PCM
FUSN

Penserra Capital Management’s Fusion Pharmaceuticals Inc. Common Shares FUSN Stock Holding History

Penserra Capital Management’s Portfolio FUSN Stock Details FUSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-980
Closed -$7K – 1592
2021
Q3 		$7K Buy
980
+15
+2% +$126 ﹤0.01% 1395
2021
Q2 		$7K Buy
965
+20
+2% +$172 ﹤0.01% 1302
2021
Q1 		$10K Sell
945
-10
-1% -$117 ﹤0.01% 1038
2020
Q4 		$11K Buy
+955
New +$12K ﹤0.01% 920

Other funds holding FUSN

JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Penserra Capital Management's FUSN Position: Q4 2021 in Review

Penserra Capital Management sold out of Fusion Pharmaceuticals Inc. Common Shares (FUSN) in Q4 2021, closing a stake of 980 shares — an estimated $7K sold.

Penserra Capital Management first reported a position in FUSN in Q4 2020 and held it in 4 quarters. The position peaked at $11K in Q4 2020. 32 funds tracked by Wall St. Rank hold FUSN as of Q4 2021.

  • Penserra Capital Management reported no remaining Fusion Pharmaceuticals Inc. Common Shares position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 980 Fusion Pharmaceuticals Inc. Common Shares shares in Q4 2021, an estimated $7K.
  • Penserra Capital Management first reported a position in Fusion Pharmaceuticals Inc. Common Shares in Q4 2020 and held it in 4 quarters.
  • Penserra Capital Management's Fusion Pharmaceuticals Inc. Common Shares position peaked at $11K in Q4 2020.
  • 32 funds tracked by Wall St. Rank held Fusion Pharmaceuticals Inc. Common Shares as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.